Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue Following 153% EPS Surge
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-21. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
A 15% expansion in high-margin growth therapies to 60% of product mix offsets legacy patent cliff revenue loss, driving P/E multiple rerating for BMY.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factBristol Myers Squibb shares have gained 17% year-to-date. |
| What else was confirmed? | Reported factQ2 2026 revenue reached $12.9 billion alongside 153% year-over-year EPS growth. |
| Does the valuation support acting? | Interpretation1 stored valuation assumptions for BMY; the latest is dated 2026-08-06. |
| What would change the assessment? | UnknownBristol Myers Squibb clinical pipeline readouts — Medical congress data updates regarding growth portfolio label expansions |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Bristol Myers Squibb shares have gained 17% year-to-date.
- · Q2 2026 revenue reached $12.9 billion alongside 153% year-over-year EPS growth.
- · The company growth portfolio of newer drugs expanded 15% year-over-year and now accounts for nearly 60% of total revenue, mitigating patent expiration drag.
Public research record
Research framework · page evidenceCompleted event assessment
earnings multiple expansion on replacement of mature drug revenues by new growth therapies
| Type | Claim | Scope |
|---|---|---|
| Assumption | Bristol Myers Squibb shares have gained 17% year-to-date. | 2026-09-21 |
| Interpretation | earnings multiple expansion on replacement of mature drug revenues by new growth therapies | BMY |
Countercase, invalidators, and sources
Growth portfolio sales accelerate above 18% annualized, driving further consensus earnings upgrades and P/E rerating toward peer medians.
- · Bristol Myers Squibb clinical pipeline readouts — Medical congress data updates regarding growth portfolio label expansions
- Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder · 2026-09-20
What remains unresolved
- Base path
- Growth portfolio expands at 12-15% annually, steadily offsetting mature product erosion through fiscal 2027.
- Adverse path
- Pricing pressure or clinical setbacks on next-generation therapies reduce growth portfolio momentum, re-exposing revenue to patent cliff risks.
- Supportive path
- Growth portfolio sales accelerate above 18% annualized, driving further consensus earnings upgrades and P/E rerating toward peer medians.
- · Bristol Myers Squibb clinical pipeline readouts — Medical congress data updates regarding growth portfolio label expansionsthis week
Evidence
- Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder2026-09-20
“Bristol Myers Squibb (BMY) is up 17% this year and trades at a discount to peers despite strong Q2 performance with $12.9B revenue and 153% EPS growth. The company's growth portfolio of newer drugs now accounts for nearly 60% of revenue and grew 15% year-over-year”
Supports: BMY up 17% YTD, Q2 revenue $12.9B, EPS up 153%, growth portfolio reaches nearly 60% of revenue (+15% YoY).